Physician profile
Saad E Shammas
NPI 1124319298
$2,964.46
in general payments reported to CMS, 2019-2025
25 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $66.22 · 2021: $82.44 · 2022: $359 · 2023: $496 · 2024: $347 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.05 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $631.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $307.95 | 2019-2023 | Shingrix, Arexvy |
| Amgen INC. | $226.37 | 2023-2025 | Repatha, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $215.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $205.65 | 2019-2022 | |
| Exact Sciences Corporation | $73.96 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $70.84 | 2021-2023 | Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.02 | 2022-2025 | Xifaxan |
| Abbvie INC. | $59.92 | 2021-2022 | |
| Amarin Pharma, INC. | $57.34 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $52.80 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $40.13 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $39.38 | 2024-2025 | Nuzyra |
| Mannkind Corporation | $28.45 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.53 | 2019 | |
| Inspire Medical Systems, INC. | $27.07 | 2024 | Inspire |
| Photonicare INC | $23.12 | 2023 | Otosight Middle Ear Scope |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.65 | 2023 | Quviviq |
| Pfizer INC. | $20.51 | 2025 | |
| Abbott Laboratories | $19.37 | 2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $17.86 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.67 | 2019 | |
| Astellas Pharma US INC | $16.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Shammas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.